8-K: Avidity Biosciences Announces Positive Topline Data from Phase 1/2 EXPLORE44 Trial of Del-zota in Duchenne Muscular Dystrophy

Avidity Biosciences reports positive topline data from its Phase 1/2 EXPLORE44 trial of delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD44), showing promising results in dystrophin production and safety.

Summary

• Avidity Biosciences announced topline data from the Phase 1/2 EXPLORE44 trial of del-zota in patients with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44).
• The trial demonstrated consistent delivery of phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle.
• There was a 40% increase in exon 44 skipping (37% at 5 mg/kg and 43% at 10 mg/kg).
• Dystrophin production increased by 25% of normal at both the 5 mg/kg and 10 mg/kg dose levels.
• Creatine kinase levels were reduced to near normal, with greater than 80% reduction compared to baseline, at both dose levels.
• Del-zota showed favorable safety and tolerability results.
• Enrollment in the EXPLORE44-OLE study is complete.
• The company plans to present functional data from the EXPLORE44-OLE study in the fourth quarter of 2025.
• Avidity has selected the 5 mg/kg every six weeks dose for ongoing and future clinical studies.
• The company plans to submit a Biologics License Application (BLA) by the end of 2025 and is pursuing an accelerated approval path in the United States.

Sentiment

Score: 8

Explanation: The document presents positive topline data from a clinical trial, indicating potential for a new treatment for Duchenne muscular dystrophy. The company is moving forward with regulatory submissions, suggesting confidence in the product's prospects. However, risks and uncertainties inherent in drug development temper the overall sentiment.

Positives

• Consistent delivery of PMOs to skeletal muscle was observed, with tissue concentrations of approximately 200nM at both dose levels.
• A 40% increase in exon 44 skipping was achieved.
• Dystrophin production increased by approximately 25% of normal.
• Creatine kinase levels were reduced by greater than 80% compared to baseline.
• Favorable safety and tolerability were demonstrated.
• The company is aligned on a path for accelerated approval in the U.S.

Negatives

• One participant discontinued due to a serious adverse event of anaphylaxis.
• One participant discontinued due to moderate infusion-related reactions (IRRs).

Risks

• Additional data related to del-zota may be inconsistent with the data produced as of the date of the report.
• Data delivered to regulators may not support del-zota's advancement in the desired timeline, or at all.
• Unexpected adverse side effects or inadequate efficacy of del-zota may delay or limit its development, regulatory approval, and/or commercialization.
• Potential delays in clinical trial activity could impact timelines.
• The company's dependence on third parties in connection with clinical testing and product manufacturing poses a risk.
• Regulatory developments in the United States and foreign countries could impact the approval process.

Future Outlook

Avidity plans to submit a BLA by the end of 2025 and is pursuing an accelerated approval path for del-zota in the United States. The company also plans to present functional data from the EXPLORE44-OLE study in the fourth quarter of 2025.

Management Comments

• Avidity understands the responsibility to get treatments to patients as quickly as possible.
• Del-zota sets the foundation for sequential neuromuscular launches.

Industry Context

The announcement positions Avidity Biosciences as a potential leader in RNA therapeutics for neuromuscular diseases, particularly Duchenne muscular dystrophy. The positive data from the EXPLORE44 trial could give Avidity a competitive edge in the DMD treatment landscape, which includes companies developing gene therapies and exon-skipping drugs.

Comparison to Industry Standards

• The 25% increase in dystrophin production is notable compared to some existing exon-skipping therapies, although direct comparisons are challenging due to differences in trial design and patient populations.
• The reduction in creatine kinase levels to near normal is a positive indicator of reduced muscle damage, potentially setting a new standard for DMD44 treatment.
• The company is aiming to compete with companies such as Sarepta Therapeutics, which has several approved exon-skipping therapies for DMD.

Stakeholder Impact

• Positive results could significantly improve the quality of life for patients with DMD44 and their families.
• Successful commercialization of del-zota would benefit Avidity's shareholders.
• The company's employees may experience increased job security and growth opportunities.

Next Steps

• Present functional data from the EXPLORE44-OLE study in the fourth quarter of 2025.
• Submit a Biologics License Application (BLA) by the end of 2025.
• Continue pursuing an accelerated approval path for del-zota in the United States.
• Advance additional exons; DMD45 in IND-enabling studies.

Key Dates